Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Fulton County Health Center
mi
from
Wauseon, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Fulton County Health Center
mi
from
Wauseon, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mount Carmel St. Ann's Cancer Center
mi
from
Westerville, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mount Carmel St. Ann's Cancer Center
mi
from
Westerville, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Clinton Memorial Hospital
mi
from
Wilmington, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Clinton Memorial Hospital
mi
from
Wilmington, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital at Wilkes-Barre
mi
from
Wilkes-Barre, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital at Wilkes-Barre
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Meeker County Memorial Hospital
mi
from
Litchfield, MN
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Meeker County Memorial Hospital
mi
from
Litchfield, MN
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hollywood, FL
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Tampa, FL
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Basking Ridge, NY
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Basking Ridge, NY
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Commack, NY
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Commack, NY
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rockville Centre, NY
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sleepy Hollow, NY
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
Cancer Prevention and Treatment Demonstration for Hispanic Medicare Eligible Beneficiaries - CMS
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
Cancer Prevention and Treatment Demonstration for Hispanic Medicare Eligible Beneficiaries - CMS
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Risk Communication Within Mexican-American Families
The Role of Family History and Culture in Communal Coping Within Mexican-American Families
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Risk Communication Within Mexican-American Families
The Role of Family History and Culture in Communal Coping Within Mexican-American Families
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates
mi
from
Phoenix, AZ
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Northern AZ Hematology Oncology Associates-AOA
mi
from
Sedona, AZ
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Northern AZ Hematology Oncology Associates-AOA
mi
from
Sedona, AZ
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
St. Jude Hertiage Medical Group
mi
from
Fullerton, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
St. Jude Hertiage Medical Group
mi
from
Fullerton, CA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Wilshire Oncology Medical Group
mi
from
La Verne, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Click here to add this to my saved trials